激素受体/人表皮生长因子受体2阳性乳腺癌治疗研究进展

doi:10.12114/j.issn.1007-9572.2019.00.744

摘要/Abstract

摘要： 乳腺癌是我国女性最常见的恶性肿瘤，根据雌激素受体（ER）和孕激素受体（PR）的表达以及人表皮生长因子受体2（HER2）基因的扩增状态，乳腺癌被分为多个分子亚型。不同的亚型预后也不同，其中HER2阳性（+）乳腺癌与HER2阴性（-）乳腺癌相比，更具侵袭性，且预后更差。激素受体（HR）+/HER2+乳腺癌由于在HR与HER2信号通路之间存在交互转导通路，以致内分泌治疗及抗HER2治疗相互影响、制约。如何合理而有效地治疗HR+/HER2+乳腺癌成为乳腺癌治疗的难点之一。本文简述了HR+/HER2+乳腺癌的治疗现状以及在抗HER2治疗、内分泌治疗、免疫治疗、磷脂酰肌醇3-激酶（PI3K）/雷帕霉素靶蛋白（mTOR）通路抑制剂等方面的探索之路。

关键词: 乳腺肿瘤；激素受体；受体, 雌激素；孕激素受体；人表皮生长因子受体2；治疗；综述

Abstract: Breast Cancer is the most common cancer among women in China.According to the expression of estrogen receptor（ER）and progesterone receptor（PR） and the status of human epidermal growth factor receptor 2（HER2） gene amplification，breast cancer has been classified into various molecular subtypes.And the prognosis of different subtypes is also different.HER2 positive breast cancer behaves more aggressively and has a worse prognosis than HER2 negative breast cancer.Moreover，there are interactive crosstalks between HR and HER2 signaling pathways so that endocrine therapy and anti-HER2 therapy could influence and restrict each other.Nowadays，how to treat HR+/HER2+ breast cancer reasonably and effectively has been one of the difficulties in the treatment of breast cancer.In this article，the treatment situation of HR+/HER2+ breast cancer and the exploration of anti-HER2 therapy，endocrine therapy，immunotherapy，PI3K/mTOR pathway inhibitors，and other aspects associated with HR+/HER2+ breast cancer have been briefly described.

Key words: Breast neoplasms；Hormone receptor；Receptors, estrogen；Progesterone receptor；Human epidermal growth factor receptor 2；Therapy；Review

伍雁琦,罗婷. 激素受体/人表皮生长因子受体2阳性乳腺癌治疗研究进展[J]. 中国全科医学, 2021, 24(8): 1028-1032. DOI: 10.12114/j.issn.1007-9572.2019.00.744.
WU Yanqi,LUO Ting. Research Progress in the Treatment of Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive Breast Cancer　[J]. Chinese General Practice, 2021, 24(8): 1028-1032. DOI: 10.12114/j.issn.1007-9572.2019.00.744.

参考文献

［1］郑荣寿，孙可欣，张思维，等．2015年中国恶性肿瘤流行情况分析［J］．中华肿瘤杂志，2019，41（1）：19-28．DOI：10.3760/cma.j.issn.0253-3766.2019.01.005.
ZHENG R S，SUN K X，ZHANG S W，et al．Report of cancer epidemiology in China，2015［J］．Chinese Journal of Oncology，2019，41（1）：19-28．DOI：10.3760/cma.j.issn.0253-3766.2019.01.005.
［2］OWENS M A，HORTEN B C，DA SILVA M M.HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues［J］．Clin Breast Cancer，2004，5（1）：63-69.
［3］PRAT A，BASELGA J.The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2［J］．Nat Clin Pract Oncol，2008，5（9）：531-542．DOI：10.1038/ncponc1179.
［4］LAL P，TAN L K，CHEN B Y.Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3，655 invasive breast carcinomas［J］．Am J Clin Pathol，2005，123（4）：541-546．DOI：10.1309/YMJ3-A83T-B39M-RUT9.
［5］HOWLADER N，ALTEKRUSE S F，LI C I，et al．US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status［J］．J Natl Cancer Inst，2014，106（5）：dju055．DOI：10.1093/jnci/dju055.
［6］VICI P，PIZZUTI L，NATOLI C，et al．Triple positive breast cancer：a distinct subtype?［J］．Cancer Treat Rev，2015，41（2）：69-76．DOI：10.1016/j.ctrv.2014.12.005.
［7］OSBORNE C K，SCHIFF R.Mechanisms of endocrine resistance in breast cancer［J］．Annu Rev Med，2011，62：233-247．DOI：10.1146/annurev-med-070909-182917.
［8］DE LAURENTIIS M，ARPINO G，MASSARELLI E，et al．A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer［J］．Clin Cancer Res，2005，11（13）：4741-4748．DOI：10.1158/1078-0432.CCR-04-2569.
［9］ARPINO G，WIECHMANN L，OSBORNE C K，et al．Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family：molecular mechanism and clinical implications for endocrine therapy resistance［J］．Endocr Rev，2008，29（2）：217-233．DOI：10.1210/er.2006-0045.
［10］LOI S，DAFNI U，KARLIS D，et al．Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab：a secondary analysis of the HERA trial［J］．JAMA Oncology，2016，2（8）：1040-1047．DOI：10.1001/jamaoncol.2016.0339.
［11］VICI P，PIZZUTI L，SPERDUTI I，et al．“Triple positive” early breast cancer：an observational multicenter retrospective analysis of outcome［J］．Oncotarget，2016，7（14）：17932-17944．DOI：10.18632/oncotarget.7480.
［12］ALQAISI A，CHEN L，ROMOND E，et al．Impact of estrogen receptor（ER） and human epidermal growth factor receptor-2（HER2） co-expression on breast cancer disease characteristics：implications for tumor biology and research［J］．Breast Cancer Res Treat，2014，148（2）：437-444．DOI：10.1007/s10549-014-3145-x.
［13］YOU S H，CHAE B J，EOM Y H，et al．Clinical differences in triple-positive operable breast cancer subtypes in Korean patients：an analysis of Korean breast cancer registry data［J］．J Breast Cancer，2018，21（4）：415-424．DOI：10.4048/jbc.2018.21.e53.
［14］刘海盟，王晓珍，李嗣杰，等．三阳性乳腺癌与Her-2过表达型乳腺癌预后对比的临床研究［J］．中国实验诊断学，2018，22（4）：615-617．DOI：10.3969/j.issn.1007-4287.2018.04.014.http：//cdmd.cnki.com.cn/Article/CDMD-10183-1018218991.htm.
［15］MONTEMURRO F，DI COSIMO S，ARPINO G.Human epidermal growth factor receptor 2（HER2）-positive and hormone receptor-positive breast cancer：new insights into molecular interactions and clinical implications［J］．Ann Oncol，2013，24（11）：2715-2724．DOI：10.1093/annonc/mdt287.
［16］CORTES J，BASELGA J.How to treat hormone receptor-positive，human epidermal growth factor receptor 2-amplified breast cancer［J］．J Clin Oncol，2009，27（33）：5492-5494．DOI：10.1200/JCO.2009.23.8089.
［17］SLAMON D J，LEYLAND-JONES B，SHAK S，et al．Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2［J］．N Engl J Med，2001，344（11）：783-792．DOI：10.1056/NEJM200103153441101.
［18］VERMA S，MILES D，GIANNI L，et al．Trastuzumab emtansine for HER2-positive advanced breast cancer［J］．N Engl J Med，2012，367（19）：1783-1791．DOI：10.1056/nejmoa1209124.
［19］BASELGA J，CORTéS J，KIM S B，et al．Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer［J］．N Engl J Med，2012，366（2）：109-119．DOI：10.1056/NEJMoa1113216.
［20］CAMERON D，PICCART-GEBHART M J，GELBER R D，et al．
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer：final analysis of the HERceptin Adjuvant（HERA） trial［J］．Lancet，2017，389（10075）：1195-1205．DOI：10.1016/S0140-6736（16）32616-2.
［21］GIANNI L，EIERMANN W，SEMIGLAZOV V，et al．Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer（NOAH）：follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort［J］．Lancet Oncol，2014，15（6）：640-647．DOI：10.1016/S1470-2045（14）70080-4.
［22］VON MINCKWITZ G，PROCTER M，DE AZAMBUJA E，et al．Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer［J］．N Engl J Med，2017，377（2）：122-131．DOI：10.1056/nejmoa1703643.
［23］GIANNI L，PIENKOWSKI T，IM Y H，et al．5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer（NeoSphere）：a multicentre，open-label，phase 2 randomised trial［J］．Lancet Oncol，2016，17（6）：791-800．DOI：10.1016/S1470-2045（16）00163-7.
［24］SWAIN S M，BASELGA J，KIM S B，et al．Pertuzumab，trastuzumab，and docetaxel in HER2-positive metastatic breast cancer［J］．N Engl J Med，2015，372（8）：724-734．DOI：10.1056/NEJMoa1413513.
［25］PEREZ E A，BARRIOS C，EIERMANN W，et al．Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive，advanced breast cancer：primary results from the phaseⅢ MARIANNE study［J］．J Clin Oncol，2017，35（2）：141-148．DOI：10.1200/JCO.2016.67.4887.
［26］DIéRAS V，MILES D，VERMA S，et al．Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer（EMILIA）：a descriptive analysis of final overall survival results from a randomised，open-label，phase 3 trial［J］．Lancet Oncol，2017，18（6）：732-742．DOI：10.1016/S1470-2045（17）30312-1.
［27］KROP I E，KIM S B，GONZáLEZ-MARTíN A，et al．Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer（TH3RESA）：a randomised，open-label，phase 3 trial［J］．Lancet Oncol，2014，15（7）：689-699．DOI：10.1016/S1470-2045（14）70178-0.
［28］HURVITZ S A，MARTIN M，SYMMANS W F，et al．Neoadjuvant trastuzumab，pertuzumab，and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer（KRISTINE）：a randomised，open-label，multicentre，phase 3 trial［J］．Lancet Oncol，2018，19（1）：115-126．DOI：10.1016/S1470-2045（17）30716-7.
［29］SCHNEEWEISS A，CHIA S，HICKISH T，et al．Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer：a randomized phase Ⅱcardiac safety study（TRYPHAENA）［J］．Ann Oncol，2013，24（9）：2278-2284．DOI：10.1093/annonc/mdt182.
［30］中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会（CSCO）乳腺癌诊疗指南（2019）［M］．北京：人民卫生出版社，2019.
［31］National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology.Breast cancer，version 2.2019［M］．https：//www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
［32］CARDOSO F，SENKUS E，COSTA A，et al．4th ESO-ESMO international consensus guidelines for advanced breast cancer（ABC 4）［J］．Ann Oncol，2018，29（8）：1634-1657．DOI：10.1093/annonc/mdy192.
［33］KAUFMAN B，MACKEY J R，CLEMENS M R，et al．Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive，hormone receptor-positive metastatic breast cancer：results from the randomized phaseⅢ TAnDEM study［J］．J Clin Oncol，2009，27（33）：5529-5537．DOI：10.1200/JCO.2008.20.6847.
［34］SWAIN S M，KIM S B，CORTéS J，et al．Pertuzumab，trastuzumab，and docetaxel for HER2-positive metastatic breast cancer（CLEOPATRA study）：overall survival results from a randomised，double-blind，placebo-controlled，phase 3 study［J］．Lancet Oncol，2013，14（6）：461-471．DOI：10.1016/S1470-2045（13）70130-X.
［35］RIMAWI M，FERRERO J M，DE LA HABA-RODRIGUEZ J，et al．First-line trastuzumab plus an aromatase inhibitor，with or without pertuzumab，in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer（PERTAIN）：a randomized，open-label phase Ⅱ trial［J］．J Clin Oncol，2018，36（28）：2826-2835．DOI：10.1200/JCO.2017.76.7863.
［36］JOHNSTON S R D，HEGG R，IM S A，et al．PhaseⅢ，randomized study of dual human epidermal growth factor receptor 2（HER2） blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive，hormone receptor-positive metastatic breast cancer：ALTERNATIVE［J］．J Clin Oncol，2018，36（8）：741-748．DOI：10.1200/JCO.2017.74.7824.
［37］FINN R S，DERING J，CONKLIN D，et al．PD 0332991，a selective cyclin D kinase 4/6 inhibitor，preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro［J］．Breast Cancer Res，2009，11（5）：R77．DOI：10.1186/bcr2419.
［38］SLEDGE G W Jr，TOI M，NEVEN P，et al．MONARCH 2：abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy［J］．J Clin Oncol，2017，35（25）：2875-2884．DOI：10.1200/JCO.2017.73.7585.
［39］GOEL S，WANG Q，WATT A C，et al．Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors［J］．Cancer Cell，2016，29（3）：255-269．DOI：10.1016/j.ccell.2016.02.006.
［40］WITKIEWICZ A K，COX D，KNUDSEN E S.CDK4/6 inhibition provides a potent adjunct to HER2-targeted therapies in preclinical breast cancer models［J］．Genes Cancer，2014，5（7/8）：261-272．DOI：10.18632/genesandcancer.24.
［41］GIANNI L，BISAGNI G，COLLEONI M，et al．Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive，ER-positive breast cancer（NA-PHER2）：an exploratory，open-label，phase 2 study［J］．Lancet Oncol，2018，19（2）：249-256．DOI：10.1016/S1470-2045（18）30001-9.
［42］SOLTI Breast Cancer Research Group.Study of palbociclib and trastuzumab with endocrine therapy in HER2-positive metastatic breast cancer［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT02448420?cond=PATRICIA&rank=1.
［43］Alliance Foundation Trials，LLC.Randomized，Open Label，Clinical Study of the Targeted Therapy，Palbociclib，to treat metastatic breast cancer（PATINA）［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT02947685?term=PATINA&rank=1.
［44］Eli Lilly and Company.A study of abemaciclib（LY2835219） in women with HR+，HER2+ locally advanced or metastatic breast cancer（monarcHER）［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT02675231?term=monarcHER&rank=1.
［45］International Breast Cancer Study Group.To reduce the use of chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer（TOUCH）［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT03644186?term=TOUCH&cond=Breast+Cancer&rank=1.
［46］International Breast Cancer Study Group.Anti-PD-1 monoclonal antibody in advanced，trastuzumab-resistant，HER2-positive breast cancer（PANACEA）［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT02129556?term=PANACEA&rank=3.
［47］Fondazione Michelangelo.Neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer（APTneo）［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT03595592?term=APTneo&rank=1.
［48］National Cancer Institute（NCI）.Paclitaxel，trastuzumab，and pertuzumab with or without atezolizumab in treating patients with metastatic breast cancer［EB/OL］．［2019-10-11］．https：//clinicaltrials.gov/ct2/show/NCT03199885?cond=Breast+Cancer&intr=Atezolizumab+Trastuzumab&rank=5.
［49］YARDLEY D A，NOGUCHI S，PRITCHARD K I，et al．Everolimus plus exemestane in postmenopausal patients with HR（+） breast cancer：BOLERO-2 final progression-free survival analysis［J］．Adv Ther，2013，30（10）：870-884．DOI：10.1007/s12325-013-0060-1.
［50］HURVITZ S A，ANDRE F，JIANG Z F，et al．Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer（BOLERO-1）：a phase 3，randomised，double-blind，multicentre trial［J］．Lancet Oncol，2015，16（7）：816-829．DOI：10.1016/S1470-2045（15）00051-0.
［51］ANDRé F，O'REGAN R，OZGUROGLU M，et al．Everolimus for women with trastuzumab-resistant，HER2-positive，advanced breast cancer（BOLERO-3）：a randomised，double-blind，placebo-controlled phase 3 trial［J］．Lancet Oncol，2014，15（6）：580-591．DOI：10.1016/S1470-2045（14）70138-X.
［52］ANDRé F，HURVITZ S，FASOLO A，et al．Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers：combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3［J］．J Clin Oncol，2016，34（18）：2115-2124．DOI：10.1200/JCO.2015.63.9161.
［53］LOIBL S，DE LA PENA L，NEKLJUDOVA V，et al．Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer：a randomised，double-blind，placebo-controlled phase Ⅱ trial（NeoPHOEBE）［J］．Eur J Cancer，2017，85：133-145．DOI：10.1016/j.ejca.2017.08.020.
［54］SIROHI B，RASTOGI S，DAWOOD S.Buparlisib in breast cancer［J］．Future Oncol，2015，11（10）：1463-1470．DOI：10.2217/fon.15.56.
［55］JAIN S，SHAH A N，SANTA-MARIA C A，et al．Phase Ⅰ study of alpelisib（BYL-719） and trastuzumab emtansine（T-DM1） in HER2-positive metastatic breast cancer（MBC） after trastuzumab and taxane therapy［J］．Breast Cancer Res Treat，2018，171（2）：371-381．DOI：10.1007/s10549-018-4792-0.
［56］CHARI R V，MILLER M L，WIDDISON W C.Antibody-drug conjugates：an emerging concept in cancer therapy［J］．Angew Chem Int Ed Engl，2014，53（15）：3796-3827．DOI：10.1002/anie.201307628.
［57］LEWIS PHILLIPS G D，LI G M，DUGGER D L，et al．Targeting HER2-positive breast cancer with trastuzumab-DM1，an antibody-cytotoxic drug conjugate［J］．Cancer Res，2008，68（22）：9280-9290．DOI：10.1158/0008-5472.CAN-08-1776.
［58］PEDDI P F，HURVITZ S A.Trastuzumab emtansine：the first targeted chemotherapy for treatment of breast cancer［J］．Future Oncol，2013，9（3）：319-326．DOI：10.2217/fon.13.7.
［59］VON MINCKWITZ G，HUANG C S，MANO M S，et al．Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］．N Engl J Med，2019，380（7）：617-628．DOI：10.1056/NEJMoa1814017.
［60］HARBECK N，GLUZ O，CHRISTGEN M，et al．De-escalation strategies in human epidermal growth factor receptor 2（HER2）-positive early breast cancer（BC）：final analysis of the West German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase Ⅱ randomized trial-efficacy，safety，and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy（ET） versus trastuzumab plus ET［J］．J Clin Oncol，2017，35（26）：3046-3054．DOI：10.1200/JCO.2016.71.9815.